2 — HEALTHCARE SCAN
2 — HEALTHCARE SCAN
2026-04-14 | Hormuz blockade context Healthcare is splitting in two: insurers bouncing from deep lows (UNH +7.7% last week), medtech grinding lower on tariff-exposed supply chains, and pharma holding as a pseudo-defensive. The Hormuz shock doesn't change the fundamental thesis for any name here — but it does sharpen the case for domestic-supply healthcare (insurers, pharma with US manufacturing) over import-dependent medtech.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 Sector diverging — insurers bouncing, medtech in confirmed downtrend, pharma mixed |
| Key insight | VEEV is a falling knife (-49% from 52wk high, RSI 32.9, -14.5% 30D). ABT approaching oversold (RSI 32.6). UNH is the wildcard — huge bounce (+7.7% 7D) from a -47% hole. CVS and MRK are the only two names with momentum. |
Price Table
| Stock | Price | 7D | 30D | 3M | RSI | 52wk Hi% | Trend | Status |
|---|---|---|---|---|---|---|---|---|
| SYK | $347.24 | +1.6% | -0.4% | -3.1% | 55.8 | -14.2% | strong-down | 🟡 Bouncing |
| ISRG | $458.96 | -1.4% | -5.1% | -16.1% | 42.4 | -24.0% | strong-down | 🟡 Weak |
| MDT | $88.00 | +0.3% | +0.5% | -10.2% | 47.5 | -17.2% | strong-down | 🟡 Neutral |
| DXCM | $63.12 | +1.3% | -4.9% | -9.4% | 40.3 | -29.9% | strong-down | 🟡 Weak |
| ABT | $100.69 | -2.3% | -8.4% | -19.0% | 32.6 | -27.6% | strong-down | 🟠 Near Oversold |
| PFE | $27.34 | -4.5% | +2.7% | +8.7% | 50.6 | -4.9% | strong-up | 🟢 Resilient |
| MRK | $120.15 | +0.3% | +4.1% | +9.0% | 53.8 | -4.0% | strong-up | 🟢 Leader |
| LLY | $929.55 | +0.8% | -6.0% | -13.3% | 45.2 | -18.0% | weak-down | 🟡 Pullback |
| GILD | $139.03 | -1.0% | -4.3% | +12.7% | 46.5 | -11.6% | weak-down | 🟡 Neutral |
| AMGN | $349.82 | +1.1% | -4.5% | +7.1% | 45.8 | -10.6% | weak-down | 🟡 Neutral |
| BIIB | $176.37 | -2.0% | -3.8% | +4.2% | 44.1 | -12.9% | weak-down | 🟡 Neutral |
| JNJ | $237.96 | -1.9% | -2.2% | +9.5% | 45.5 | -5.5% | weak-down | 🟡 Defensive |
| UNH | $313.00 | +7.7% | +9.6% | -5.8% | 67.6 | -47.5% | up | 🟠 Bounce Watch |
| CVS | $78.09 | +8.3% | +3.0% | -0.8% | 59.5 | -8.3% | strong-up | 🟢 Working |
| VEEV | $158.45 | -13.3% | -14.5% | -27.6% | 32.9 | -49.0% | strong-down | 🔴 Breakdown |
| TMO | $514.23 | +1.6% | +9.4% | -17.2% | 58.9 | -20.2% | weak-up | 🟡 Recovery |
| VRTX | $440.05 | -0.6% | -5.6% | -2.1% | 44.1 | -13.9% | weak-down | 🟡 Neutral |
| MRNA | $50.68 | +3.0% | -4.9% | +24.9% | 49.9 | -14.9% | strong-up | 🟢 Emerging |
| GRDN | $39.49 | -0.1% | +19.9% | +31.1% | 63.6 | -4.5% | strong-up | 🟠 Extended |
Tier Analysis
Tier 1 — Momentum Leaders (MRK, CVS, PFE, GRDN) MRK is the cleanest name in healthcare right now — RSI 53.8, +4.1% 30D, +9% 3M, only -4% from 52wk high, golden cross, strong-up trend. Keytruda + Winrevair are compounding. CVS bounced hard (+8.3% 7D), restructuring thesis gaining traction. PFE is quiet strength — golden cross, strong-up, nearly at 52wk high. GRDN is speculative but momentum is real (+31% 3M, RSI 63.6, +38% vs SMA200).
Tier 2 — Defensibles (JNJ, GILD, AMGN) These are cash-flow stalwarts in a risk-off environment. None are exciting, but none are broken. JNJ at -5.5% from 52wk high with RSI 45.5 is a quiet accumulation candidate.
Tier 3 — Approaching Entry (ABT, DXCM) ABT — RSI 32.6, -19% 3M, -27.6% from 52wk high, death cross. This is deep. The diagnostic device thesis is intact long-term but there's tariff exposure on device supply chains. Watch for RSI to breach 30 for capitulation signal. DXCM — RSI 40.3, -29.9% from 52wk high. CGM market is growing but competition from Abbott's Libre is intensifying. Not an obvious buy yet.
Tier 4 — Broken / Avoid VEEV — RSI 32.9, -13.3% 7D, -14.5% 30D, -27.6% 3M, -49% from 52wk high, death cross, -35.5% below SMA200. This is structural, not cyclical. Pharma SaaS is being repriced post-tariff uncertainty and competitive pressure. Knife-catcher territory. ISRG — Death cross, -24% from 52wk high, -16% 3M. Surgical robotics is not breaking but the premium multiple is compressing.
Tier 5 — Wild Card UNH — RSI 67.6, +7.7% 7D, but -47.5% from 52wk high and death cross. Enormous bounce on oversold conditions and legal settlement headlines. This is a mean-reversion trade, not a thesis trade. RSI approaching 70 — don't chase.
Entry Zones
NEAR OVERSOLD (RSI 30-40)
| Stock | Current | Zone | RSI | 30D | Action | Notes |
|---|---|---|---|---|---|---|
| ABT | $100.69 | <$95 | 32.6 | -8.4% | 🔍 Watch | Await RSI < 30 capitulation; tariff exposure to watch |
| DXCM | $63.12 | <$60 | 40.3 | -4.9% | 🔍 Watch | CGM competition; not yet a clean entry |
| ISRG | $458.96 | <$440 | 42.4 | -5.1% | 🔍 Watch | Premium multiple compressing; needs RSI flush |
| VEEV | $158.45 | Avoid | 32.9 | -14.5% | ❌ Don't Buy | Structural breakdown, not a dip |
LEADERS (Trend Intact)
| Stock | Current | Zone | RSI | 30D | Action | Notes |
|---|---|---|---|---|---|---|
| MRK | $120.15 | <$115 | 53.8 | +4.1% | 🔒 Hold | Best-in-class; only buy on meaningful pullback |
| CVS | $78.09 | $70-75 | 59.5 | +3.0% | 🔒 Hold | Restructuring on track; don't chase here |
| PFE | $27.34 | <$26 | 50.6 | +2.7% | 📈 Accumulate | Near 52wk high, golden cross, cheap multiple |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| 🔒 HOLD | MRK, CVS, PFE | Momentum leaders, golden cross, trend intact |
| 📈 ACCUMULATE | JNJ, GILD | Defensive cash flows, mild RSI weakness |
| 🔍 WATCH | ABT | RSI 32.6 — approaching oversold, await flush |
| 🔍 WATCH | TMO | Recovery trend forming, +9.4% 30D |
| 🔍 WATCH | MRNA | mRNA re-rate continuing — watch RSI hold |
| ⚠️ AVOID | UNH | RSI 67.6 — don't chase the bounce at -47% hole |
| ⚠️ AVOID | GRDN | +31% 3M, RSI 63.6 — extended, speculative |
| ❌ DON'T BUY | VEEV | Structural breakdown — -49% from high, death cross |
| ❌ DON'T BUY | ISRG | Premium multiple compression still in progress |
Related
10 eventsNo direct external sources are attached to this read.